Zenas BioPharma Launches As A Cross-border Biopharma Company
Zenas BioPharma has launched a cross-border biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies for patients in China and throughout the world. Zenas aims for rapid advancement in its current portfolio and to establish its global leadership with an expanded pipeline coupled with a strong footprint in China.
Zenas was founded and initially funded by Tellus BioVentures, LLC and Fairmount Funds Management LLC and is additionally backed by a syndicate of leading global life science investment funds including Quan Capital, WuXi Biologics Healthcare Ventures and Wellington Management.
Lonnie Moulder, Executive Chairman and Interim Chief Executive Officer at Zenas says, “We are excited about the launch of Zenas BioPharma and its pipeline of differentiated product candidates. These potentially best-in-class products are intended to bring innovation to patients with underserved diagnoses while also maximizing value across the healthcare ecosystem,” said Mr. Moulder. “The expanding Zenas leadership team and our network of business partners will drive operational excellence to deliver potentially transformative therapies to improve the lives of people living with autoimmune and rare diseases.”
Zenas debuts with a deep pipeline of seven innovative immune-based therapeutics that will continue to expand through a successful business development strategy. Zenas owns worldwide rights to three of the seven pipeline programs, which uniquely positions the Company to be global in scope.
Zenas innovation is defined by the selection of product candidates that are designed with best-in-class potential and then advanced utilizing differentiated development and commercial strategies to address patient needs AND the value requirements of the dynamic healthcare environment.